Edgewise Therapeutics, Inc. (EWTX) /
The debt of Edgewise Therapeutics, Inc. over the past 6 years
Chart Edgewise Therapeutics, Inc.: liquid cash, total debt, net cash, fiscal 2020–2025 Open the chart →At the end of fiscal 2025, the latest fiscal year on file, Edgewise Therapeutics, Inc. had liquid cash of $530.11M and total debt of $0: net cash of $530.11M. It had more liquid cash than debt at all 6 year-ends shown.
Year by year
| Fiscal year | Liquid cash | Total debt* | Net cash* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | $530.11M* | $0 | $530.11M |
| 2024ended Dec 31, 2024 | $470.17M* | $0 | $470.17M |
| 2023ended Dec 31, 2023 | $318.39M* | $0 | $318.39M |
| 2022ended Dec 31, 2022 | $351.95M* | $0 | $351.95M |
| 2021ended Dec 31, 2021 | $280.79M* | $0 | $280.79M |
| 2020ended Dec 31, 2020 | $129.09M* | $0 | $129.09M |
Fiscal years as Edgewise Therapeutics, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Edgewise Therapeutics, Inc.
- The profitability of Edgewise Therapeutics, Inc.
- The cash flow of Edgewise Therapeutics, Inc.
- All of Edgewise Therapeutics, Inc.'s financials, charted
Companies of a similar size
- BBWIBATH & BODY WORKS, INC.
- KNTKKINETIK HOLDINGS INC.
- ARQTARCUTIS BIOTHERAPEUTICS, INC.
- FRSHFreshworks Inc.
- BYNDBEYOND MEAT, INC.
Not investment advice. This page shows what Edgewise Therapeutics, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.